CClinicalTrials.gg
RecruitingNCT06604793Updated Sep 20, 2024

Creatine Supplementation in Young Healthy Adults

An interventional study of Creatine and Placebo in Improve Muscle Performance in Young Adults, sponsored by University of Regina. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by University of Regina · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Study summary

The purpose is to compare the effects of bolus ingestion (5 grams) vs. intermittent ingestion (2 x 2.5 grams) of creatine supplementation vs. placebo for 21 days on measures of body composition (lean tissue mass-indicator of muscle mass, total body water) and muscle performance (i.e., power, strength, endurance).

Read the detailed description

Creatine is a naturally occurring compound produced in the liver and brain. Creatine can also be found in food products such as red meat and seafood or through commercially available manufactured creatine products (i.e. creatine supplementation).

Evidence-based research shows that creatine supplementation improves measures of body composition and muscle performance. However, the optimal creatine supplementation protocol to achieve these benefits is unknown.

02

Conditions studied

  • Improve Muscle Performance in Young Adults
03

In context

Lead sponsor

University of Regina is the lead sponsor of 56 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • if you are 18-39 years of age
  • if you have not been performing resistance training for at least 4 weeks prior to the start of the study.

Exclusion criteria

Exclusion Criteria:

  • if you are pregnant or nursing
  • have taken creatine monohydrate within 30 days prior to the start of the study
  • if you have pre-existing allergies to the placebo (corn-starch maltodextrin)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Creatine Bolus

    (Serving 1: 5 grams of creatine monohydrate + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.

    Dietary Supplement: Creatine

  • Experimental
    Creatine Intermittent

    (Serving 1: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the morning; Serving 2: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the evening) for 21 days.

    Dietary Supplement: Creatine

  • Placebo comparator
    Placebo

    (Servings 1: 8 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCreatine

    Creatine monohydrate

  • Dietary supplementPlacebo

    Maltodextrin

06

What researchers measure

Primary outcomes

  1. Whole-body lean mass (kg)

    Bioelectrical impedance analysis

    Time frame: baseline, day 21

  2. Strength

    1-repetition maximum leg press and chest press (kg)

    Time frame: baseline, day 21

  3. Endurance

    Repetitions to fatigue for leg press and chest press (total number)

    Time frame: baseline, day 21

  4. Hydration

    Total body water (kg) using bioelectrical impedance analysis

    Time frame: baseline, day 21

  5. Power

    Vertical Jump (cm)

    Time frame: baseline, day 21

  6. Power

    Medicine Ball Throw (feet)

    Time frame: baseline, day 21

07

Study locations

1 of 1 sites recruiting
  • University of Regina
    Regina, Saskatchewan S4S 0A2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06604793
Lead sponsor
University of Regina
Collaborators
Iovate Health Sciences International Inc
Responsible party
Darren Candow (Professor, University of Regina) — Principal investigator
First posted
Sep 20, 2024
Start date
Aug 20, 2024
Primary completion
Jan 31, 2025 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Sep 20, 2024

Study contacts

Darren Candow
Contact
Darren.Candow@uregina.ca
306-585-4906
Darren Candow
principal investigator · University of Regina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion